Nurix Therapeutics, Inc.
NRIX
Positions held
Your positionsNRIX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Nurix Therapeutics is positioned in the growing biotechnology sector, focusing on innovative therapies that could address unmet medical needs.
- Revenue increased by 45% compared to the prior quarter, reaching $9.0 million.
- Operating margin improved to -1041.7% in the latest quarter.
- The company has a high debt-to-equity ratio of 14.441, indicating potential financial instability.
- Revenue growth has been negative at -79.5%, reflecting challenges in generating consistent income.
- The overall score indicates a 'Strong Sell' with a score of -16.00, highlighting significant bearish trends.
Fundamentals
| Market cap | $2.30B | Enterprise value | $1.92B | Trailing P/E | — | Forward P/E | -20.85 |
| PEG | — | Price / book | 5.72 | Beta | 1.82 | Dividend yield | 0.00% |
| Revenue growth | -79.5% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -10.4% |
| Profit margin | 0.0% | ROE | -80.3% | ROA | -40.1% | Debt / equity | 0.14 |
| Current ratio | 6.34 | Free cash flow | -$164.64M | Analyst recommendation | none | Mean target | $33.93 |
| 52w high | $28.23 | 52w low | $9.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $9.0M | $6.3M | $13.6M | $7.9M | $44.1M | — |
| Op margin | -1041.7% | -1479.4% | -612.0% | -1157.7% | -109.7% | — |
| Net income | -$89.5M | -$87.2M | -$78.2M | -$86.4M | -$43.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$94.2M | -$92.5M | -$83.1M | -$91.4M | -$48.3M | — |
- Revenue +45% vs prior quarter ($9.0M vs $6.3M).
- Operating margin expanded to -1041.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $84.0M | $54.5M | $77.0M | $38.6M |
| Op margin | -340.2% | -390.5% | -201.4% | -476.0% |
| Net income | -$264M | -$194M | -$144M | -$180M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$286M | -$213M | -$155M | -$184M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Is Extending the Gilead E3 Ligase Collaboration Altering The Investment Case For Nurix Therapeutics (NRIX)?
2026-10-07 · Nurix Says First Patient Enrolled in Phase 1b/2 Lymphocytic Leukemia Combination Study
2026-10-05 · Nurix Therapeutics, Gilead Sciences Agree on Two-Year Research Term Extension for Oncology Program
2026-09-29 · Nurix Therapeutics to Receive $7 Million Pfizer Collaboration Milestone Payment
2026-09-29 · Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
2026-09-21 · AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
2026-09-10 · Here's Why You Should Add NRIX Stock to Your Portfolio Now
2026-09-09 · Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why
2026-09-03 · Can KT-621 Mark a Turning Point for Kymera Therapeutics?
2026-09-01 · Nurix Therapeutics to Participate in Upcoming September Investor Conferences
Price (daily)
Full chart · RSI · MACD · patterns